CARDIOTOXICITY AND METHODS OF ITS DIAGNOSIS IN HEMATOLOGY PATIENTS (REVIEW)
Abstract
The article is devoted to the modern concept of cardiotoxicity, induced chemotherapy in patients with hematological pathology and methods of its diagnosis. The study of cardiotoxicity is one of the current trends in oncology and oncohematology, as the side effects of chemotherapy drugs on the cardiovascular system affect the quality and life expectancy of patients, regardless of the prognosis associated with oncohematological disease. While modern strategies for the treatment of oncohematological diseases make it possible to achieve stable remissions and increase the duration and quality of life of patients, such successes can be offset by an increase in mortality in this group of patients due to the development of side effects of chemotherapy in relation to the cardiovascular system. In the review problems and prospects of cardiotoxicity diagnosis in patients with hematological diseases on the background of chemotherapy are presented at modern level of medical science development. The use of such methods as three-dimensional echocardiography, echocardiography with determination of global longitudinal myocardial deformation, stress echocardiography with determination of contractile reserve, determination of troponin and natriuretic peptide levels for diagnosis of cardiotoxicity makes it possible to detect manifestations of cardiotoxicity at an earlier stage and thus will reduce mortality in patients with oncohematological profile receiving chemotherapy for non-hematological reasons.
Key words
2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines. Rossiyskiy kardiologicheskiy zhurnal = Russian journal of cardiology. 2017. 22. (3). 105–139. [In Russian].
Abidov A., Rozanski A., Hachamovitch R., Hayes S.W., Aboul-Enein F., Cohen I., Friedman J.D., Germano G., Berman D.S. Prognostic significance of dyspnea in patients referred for cardiac stress testing. N. Engl. J. Med. 2005. 353. (18). 1889–1898.
American College of Cardiology Foundation Appropriate Use Criteria Task Force. American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Societ, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American College of Chest Physicians, Douglas P.S., Garcia M.J., Haines D.E., Lai W.W., Manning W.J., Patel A.R., Picard M.H., Polk D.M., Ragosta M., Parker Ward R., Weiner R.B. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians. J. Am. Soc. Echocardiogr. 2011. 24. (3). 229–267.
Anhel N., Delgado D.H., Lipton J.H. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc. Health Risk Manag. 2017. 13. 293-303.
Armstrong G.T., Plana J.C., Zhang N., Srivastava D., Green D.M., Ness K.K., Daniel D.F., Metzger M.L., Arevalo A., Durand J.B., Joshi V., Hudson M.M., Robison L.L., Flamm S.D. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J. Clin. Oncol. 2012. 30. 2876–2884.
Auner H.W., Tinchon C., Linkesch W., Tiran A., Quehenberger F., Link H., Sill H. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann. Hematol. 2003. 82. (4). 218–222.
Bando S., Soeki T., Matsuura T., Tobiume T., Ise T., Kusunose K., Yamaguchi K., Yagi S., Fukuda D., Iwase T., Yamada H., Wakatsuki T., Shimabukuro M., Muguruma N., Takayama T., Kishimoto I., Kangawa K., Sata M. Plasma brain natriuretic peptide levels are elevated in patients with cancer. PLoS One. 2017. 12. (6). e0178607.
Bradshaw P.T., Stevens J., Khankari N., Teitelbaum S.L., Neugut A.I., Gammon M.D. Cardiovascular disease mortality among breast cancer survivors. Epidemiology. 2016. 27. (1). 6–13.
Cardinale D., Colombo A., Bacchiani G., Tedeschi I., Meroni C.A., Veglia F., Civelli M., Lamantia G., Colombo N., Curigliano G., Fiorentini C., Cipolla C.M. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015. 131. 1981-1988.
Chakraborty M., Kamath J.V., Bhattacharjee A. Pharmacodynamic interaction of green tea extract with hydrochlorothiazide against cyclophosphamide-induced myocardial damage. Toxicol. Int. 2014. 21. 196–202.
Charbonnel C., Convers-Domart R., Rigaudeau S., Taksin A.L., Baron N., Lambert J., Ghez S., Georges J.L., Farhat H., Lambert J., Rousselot P., Livarek B. Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity. Eur. Heart J. Cardiovasc. Imaging. 2017. 18. 392–401.
Cheungpasitporn W., Kopecky S.L., Specks U., Bharucha K., Fervenza F.C. Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. J. Renal Inj. Prev. 2017. 6. (1). 18–25.
Daher I.N., Kim C., Saleh R.R., Plana J.C., Yusuf S.W., Banchs J. Prevalence of abnormal echocardiographic findings in cancer patients: a retrospective evaluation of echocardiography for identifying cardiac abnormalities in cancer patients. Echocardiography. 2011. 28. 1061–1067.
Dolci A., Dominici R., Cardinale D., Sandri M. T., Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am. J. Clin. Pathol. 2008. 130. (5). 688–695.
Douglas P.S., Carr J.J., Cerqueira M.D., Cummings J.E., Gerber T.C., Mukherjee D., Taylor A.J. Developing an action plan for patient radiation safety in adult cardiovascular medicine: proceedings from the Duke University Clinical Research Institute/American College of Cardiology Foundation/American Heart Association Think Tank held on February 28. J. Am. Coll. Cardiol. 2012. 59. 1833–1847.
Fallah-Rad N., Walker J. R., Wassef A., Lytwyn M., Bohonis S., Fang T., Tian G., Kirkpatrick I. D., Singal P. K., Krahn M., Grenier D., Jassal D. S. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant traztuzumab therapy. J. Am. Coll. Cardiol. 2011. 57. (22). 2263-2270.
Galderisi M., Marra F., Esposito R., Lomoriello V.S., Pardo M., de Divitiis O. Cancer therapy and cardiotoxicity: The need of serial Doppler echocardiography. Cardiovasc. Ultrasound. 2007. 5. 4-18.
Gorcsan J., Tanaka H. Echocardiographic assessment of myocardial strain. J. Am. Coll. Cardiol. 2011. 58. (14). 1401–1413.
Gupta M., Thaler H.T., Steinherz L. Presence of prolonged dispersion of qt intervals in late survivors of childhood anthracycline therapy. Pediatr. Hematol. Oncol. 2002. 19. 533–542.
Jacobs L.D., Salgo I.S., Goonewardena S., Weinert L., Coon P., Bardo D., Gerard O., Allain P., Zamorano J.L., de Isla L.P., Mor-Avi V., Lang R.M. Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data. Eur. Heart J. 2006. 27. 460–468.
Jarfelt M. Exercise echocardiography reveals subclinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer. 2007. 49. 835-40.
Lipshultz S.E., Adams M.J., Colan S.D., Constine L.S., Herman E.H., Hsu D.T., Hudson M.M., Kremer L.C., Landy D.C., Miller T.L., Oeffinger K.C., Rosenthal D.N., Sable C.A., Sallan S.E., Singh G.K., Steinberger J., Cochran T.R., Wilkinson J.D., American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Basic Cardiovascular Sciences, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Radiolo. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013. 128. (17). 1927-95.
Lipshultz S.E., Miller T.L., Scully R.E., Lipsitz S.R., Rifai N., Silverman L.B., Colan S.D., Neuberg D.S., Dahlberg S.E., Henkel J.M., Asselin B.L., Athale U.H., Clavell L.A., Laverdiere C., Michon B., Schorin M.A., Sallan S.E. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J. Clin. Oncol. 2012. 30. (10). 1042–1049.
Manrique C.R., Park M., Tiwari N., Plana J.C., Garcia M.J. Diagnostic strategies for early recognition of cancer therapeutics-related cardiac dysfunction. Clin. Med. Insights Cardiol. 2017. 11. 1179546817697983.
Marini M.G., Cardillo M.T., Caroli A., Sonnino C., Biasucci L.M. Increasing specificity of high-sensitivity troponin: new approaches and perspectives in the diagnosis of acute coronary syndromes. J. Cardiol. 2013. 62. (4). 205–209.
McGowan J.V., Chung R., Maulik A., Piotrowska I., Walker J.M., Yellon D.M. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc. Drugs Ther. 2017. 31. 63–75.
Mellor H.R., Bell A.R., Valentin J.P., Roberts R.R.A. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol. Sci. 2011. 120. (1). 14–32.
Nakamae H., Tsumura K., Hino M., Hayashi T., Tatsumi N. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. Lancet. 2000. 355. 805–806.
Orphanos G.S., Ioannidis G.N., Ardavanis A.G. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009. 48. (7). 964-970.
Panjrath G.S., Patel V., Valdiviezo C.I., Narula N., Narula J., Jain D. Potentiation of Doxorubicin cardiotoxicity by iron loading in a rodent model. J. Am. Coll. Cardiol. 2007. 49. 2457-64.
Plana J.C., Galderisi M., Barac A., Ewer M.S., Ky B., Scherrer-Crosbie M., Ganame J., Sebag I.A., Agler D.A., Badano L.P., Banchs J., Cardinale D., Carver J., Cerqueira M., JM DC., Edvardsen T., Flamm S.D., Force T., Griffin B.P., Jerusalem G., Liu J.E., Magalhaes A., Marwick T., Sanchez L.Y., Sicari R., Villarraga H.R., Lancellotti P. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 2014. 27. (9). 911–939.
Risum N., Ali S., Olsen N.T., Jons C., Khouri M.G., Lauridsen T.K., Samad Z., Velazquez E.J., Sogaard P., Kisslo J. Variability of global left ventricular deformation analysis using vendor dependent and independent two-dimensional speckle-tracking software in adults. J. Am. Soc. Echocardiogr. 2012. 25. (11). 1195–1203.
Roffi M., Patrono C., Collet J.P., Mueller C., Valgimigli M., Andreotti F., Bax J.J., Borger M.A., Brotons C., Chew D.P., Gencer B., Hasenfuss G., Kjeldsen K., Lancellotti P., Landmesser U., Mehilli J., Mukherjee D., Storey R.F., Windecker S., Baumgartner H., Gaemperli O., Achenbach S., Agewall S., Badimon L., Baigent C., Bueno H., Bugiardini R., Carerj S., Casselman F., Cuisset T., Erol C., Fitzsimons D., Halle M., Hamm C., Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS, Lip GY, Piepoli MF, Richter D, Rosemann T., Sechtem U., Steg P.G., Vrints C., Luis Zamorano J., Management of Acute Coronary Syndromes in Patients Presenting without Persistent STSEotESoC. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the Management of Acute Coronary Syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2016. 37. (3). 267–315.
Sandri M.T., Salvatici M., Cardinale D., Zorzino L., Passerini R., Lentati P., Leon M., Civelli M., Martinelli G., Cipolla C.M. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?. Clin. Chem. 2005. 51. (8). 1405–1410.
Takase H., Dohi Y. Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship. Eur. J. Clin. Investig. 2014. 44. (3). 303–308.
Tan C., Tasaka H., Yu K.P., Murphy M.L., Karnofsky D.A. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967. (20). 333–353.
Thavendiranathan P., Grant A.D., Negishi T., Plana J.C., Popović Z.B., Marwick T.H. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J. Am. Coll. Cardiol. 2013. 61. 77–84.
Thavendiranathan P., Poulin F., Lim K.D., Plana J.C., Woo A., Marwick T.H. Use of myocardial strain imaging by standardizecardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J. Am. Coll. Cardiol. 2014. 63. (25). 2751–2768.
Varga Z.V., Ferdinandy P., Liaudet L., Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am. J. Physiol. Heart Circ. Physiol. 2015. 309. 1453–1467.
Voigt J.U., Pedrizzetti G., Lysyansky P., Marwick T.H., Houle H., Baumann R., Pedri S., Ito Y., Abe Y., Metz S., Song J.H., Hamilton J., Sengupta P.P., Kolias T.J., d'Hooge J., Aurigemma G.P., Thomas J.D., Badano L.P. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur. Heart J. Cardiovasc. Imaging. 2015. 16. 1–11.
Wang J., Nachtigal M.W., Kardami E., Cattini P.A. FGF-2 protects cardiomyocytes from doxorubicin damage via protein kinase C-dependent effects on efflux transporters. Cardiovasc. Res. 2013. 98. (1). 56-63.
Wittstein I.S., Thiemann D.R., Lima J.A., Baughman K.L., Schulman S.P., Gerstenblith G., Wu K.C., Rade J.J., Bivalacqua T.J., Champion H.C. Neurohumoral features of myocardial stunning due to sudden emotional stress. N. Engl. J. Med. 2005. 352. (6). 539–48.
Yeh E.T., Bickford C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 2009. 53. (24). 2231–2247.
Yeh E.T., Tong A.T., Lenihan D.J., Yusuf S.W., Swafford J., Champion C., Durand J.B., Gibbs H., Zafarmand A.A., Ewer M.S. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004. 29. 109. (25). 3122-31.
Zamorano J.L., Lancellotti P., Rodriguez M.D., Aboyans V., Asteggiano R., Galderisi M., Habib G., Lenihan D.J., Lip G.Y., Lyon A.R., Lopez Fernandez T., Mohty D., Piepoli M.F., Tamargo J., Torbicki A., Suter T.M., Zamorano J.L., Aboyans V., Achenbach S., Agewall S., Badimon L., Barón-Esquivias G., Baumgartner H., Bax J.J., Bueno H., Carerj S., Dean V., Erol Ç., Fitzsimons D., Gaemperli O., Kirchhof P., Kolh P., Lancellotti P., Lip G.Y., Nihoyannopoulos P., Piepoli M.F., Ponikowski P., Roffi M., Torbicki A., Vaz Carneiro A., Windecker S., Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), Document Reviewers. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur. J. Heart Fail. 2017. 19. 9–42.
Kuzmina T.P. – resident, e-mail: tatyana_kuzmina_91@bk.ru
